Nicotinamide Riboside

Nicotinamide Riboside

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Nicotinamide Riboside</th>
</tr>
<tr>
<td class="label">Study</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT03028389</td>
<td>Phase I</td>
</tr>
<tr>
<td class="label">NCT03462134</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">Form</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">NR chloride</td>
<td>100-300 mg</td>
</tr>
<tr>
<td class="label">NR bitartrate</td>
<td>250-500 mg</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Pterostilbene</td>
<td>Synergistic sirtuin activation</td>
</tr>
<tr>
<td class="label">Alpha-lipoic acid</td>
<td>Mitochondrial protection</td>
</tr>
<tr>
<td class="label">CoQ10</td>
<td>Enhanced ETC function</td>
</tr>
<tr>
<td class="label">Resveratrol</td>
<td>SIRT1 activation</td>
</tr>
<tr>
<td class="label">Age</td>
<td>Brain NAD+</td>
</tr>
<tr>
<td class="label">20 years</td>
<td>100% (baseline)</td>
</tr>
<tr>
<td class="label">40 years</td>
<td>~70%</td>
</tr>
<tr>
<td class="label">60 years</td>
<td>~50%</td>
</tr>
<tr>
<td class="label">80 years</td>
<td>~30%</td>
</tr>
<tr>
<td class="label">Sirtuin</td>
<td>Location</td>
</tr>
<tr>
<td class="label">SIRT1</td>
<td>Nucleus</td>
</tr>
<tr>
<td class="label">SIRT2</td>
<td>Cytop

Nicotinamide Riboside

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Nicotinamide Riboside</th>
</tr>
<tr>
<td class="label">Study</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT03028389</td>
<td>Phase I</td>
</tr>
<tr>
<td class="label">NCT03462134</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">Form</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">NR chloride</td>
<td>100-300 mg</td>
</tr>
<tr>
<td class="label">NR bitartrate</td>
<td>250-500 mg</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Pterostilbene</td>
<td>Synergistic sirtuin activation</td>
</tr>
<tr>
<td class="label">Alpha-lipoic acid</td>
<td>Mitochondrial protection</td>
</tr>
<tr>
<td class="label">CoQ10</td>
<td>Enhanced ETC function</td>
</tr>
<tr>
<td class="label">Resveratrol</td>
<td>SIRT1 activation</td>
</tr>
<tr>
<td class="label">Age</td>
<td>Brain NAD+</td>
</tr>
<tr>
<td class="label">20 years</td>
<td>100% (baseline)</td>
</tr>
<tr>
<td class="label">40 years</td>
<td>~70%</td>
</tr>
<tr>
<td class="label">60 years</td>
<td>~50%</td>
</tr>
<tr>
<td class="label">80 years</td>
<td>~30%</td>
</tr>
<tr>
<td class="label">Sirtuin</td>
<td>Location</td>
</tr>
<tr>
<td class="label">SIRT1</td>
<td>Nucleus</td>
</tr>
<tr>
<td class="label">SIRT2</td>
<td>Cytoplasm</td>
</tr>
<tr>
<td class="label">SIRT3</td>
<td>Mitochondria</td>
</tr>
<tr>
<td class="label">SIRT5</td>
<td>Mitochondria</td>
</tr>
<tr>
<td class="label">SIRT6</td>
<td>Nucleus</td>
</tr>
<tr>
<td class="label">SIRT7</td>
<td>Nucleolus</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT03028389</td>
<td>Phase I</td>
</tr>
<tr>
<td class="label">NCT03462134</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">NCT04149521</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">EUDAR</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT03816147</td>
<td>Phase I</td>
</tr>
<tr>
<td class="label">NCT04489095</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">NRP-PD</td>
<td>Observational</td>
</tr>
<tr>
<td class="label">Condition</td>
<td>Evidence</td>
</tr>
<tr>
<td class="label">Huntington's disease</td>
<td>Preclinical strong</td>
</tr>
<tr>
<td class="label">ALS</td>
<td>Mixed results</td>
</tr>
<tr>
<td class="label">Multiple sclerosis</td>
<td>Promising preclinical</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Oral bioavailability</td>
<td>~50-60%</td>
</tr>
<tr>
<td class="label">Time to peak (Cmax)</td>
<td>1-3 hours</td>
</tr>
<tr>
<td class="label">Half-life (t1/2)</td>
<td>3-4 hours</td>
</tr>
<tr>
<td class="label">CNS penetration</td>
<td>Moderate (brain:plasma ~0.2-0.4)</td>
</tr>
<tr>
<td class="label">Tissue distribution</td>
<td>Wide; accumulates in muscle, liver</td>
</tr>
<tr>
<td class="label">Adverse Event</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Nausea</td>
<td>5-10%</td>
</tr>
<tr>
<td class="label">Flushing</td>
<td>2-5%</td>
</tr>
<tr>
<td class="label">Headache</td>
<td>2-5%</td>
</tr>
<tr>
<td class="label">Diarrhea</td>
<td><5%</td>
</tr>
<tr>
<td class="label">Fatigue</td>
<td><5%</td>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">Metformin</td>
<td>May compete for same transporters</td>
</tr>
<tr>
<td class="label">Statins</td>
<td>No significant interaction</td>
</tr>
<tr>
<td class="label">Blood pressure meds</td>
<td>No interaction</td>
</tr>
<tr>
<td class="label">Chemotherapy</td>
<td>Theoretical concern</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Recommendation</td>
</tr>
<tr>
<td class="label">Dose</td>
<td>250-500 mg daily</td>
</tr>
<tr>
<td class="label">Form</td>
<td>NR chloride or bitartrate</td>
</tr>
<tr>
<td class="label">Timing</td>
<td>Morning with food</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>Long-term use expected</td>
</tr>
<tr>
<td class="label">Monitoring</td>
<td>Consider NAD+ testing</td>
</tr>
<tr>
<td class="label">Precursor</td>
<td>Conversion</td>
</tr>
<tr>
<td class="label">Nicotinamide riboside</td>
<td>Direct to NMN</td>
</tr>
<tr>
<td class="label">Nicotinamide mononucleotide (NMN)</td>
<td>Direct to NAD+</td>
</tr>
<tr>
<td class="label">Nicotinamide (NAM)</td>
<td>Via NAMPT</td>
</tr>
<tr>
<td class="label">Tryptophan</td>
<td>Via de novo pathway</td>
</tr>
<tr>
<td class="label">Nicotinic acid (NA)</td>
<td>Via NAPRT</td>
</tr>
<tr>
<td class="label">Year</td>
<td>Development</td>
</tr>
<tr>
<td class="label">2004</td>
<td>NR identified as NAD+ precursor</td>
</tr>
<tr>
<td class="label">2013</td>
<td>First human clinical trial</td>
</tr>
<tr>
<td class="label">2016</td>
<td>Multiple trials initiated for AD, PD</td>
</tr>
<tr>
<td class="label">2020</td>
<td>FDA fast track for ALS</td>
</tr>
<tr>
<td class="label">2023</td>
<td>Phase II AD trial results published</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Recommendation</td>
</tr>
<tr>
<td class="label">Purity</td>
<td>≥98% pure</td>
</tr>
<tr>
<td class="label">Third-party testing</td>
<td>USP, NSF, or similar</td>
</tr>
<tr>
<td class="label">Form</td>
<td>NR chloride preferred</td>
</tr>
<tr>
<td class="label">Package</td>
<td>Dark bottle, cool storage</td>
</tr>
<tr>
<td class="label">Excipients</td>
<td>Minimal, avoid allergens</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Condition</td>
</tr>
<tr>
<td class="label">NCT05322237</td>
<td>AD</td>
</tr>
<tr>
<td class="label">NCT05322189</td>
<td>PD</td>
</tr>
<tr>
<td class="label">NCT04768981</td>
<td>ALS</td>
</tr>
</table>

Nicotinamide riboside (NR) is a naturally occurring form of vitamin B3 and a precursor to nicotinamide adenine dinucleotide (NAD+)[@bieganowski2004]. NR has gained significant attention in neurodegenerative disease research due to its ability to boost cellular NAD+ levels, which decline with age and in various neurological disorders[@imai2014].

Biochemical Mechanism

NAD+ Biosynthesis Pathway

NR is converted to NAD+ through the salvage pathway:

Key Enzymes

• NRK1/2: Nicotinamide riboside kinases that phosphorylate NR to NMN
• NAMPT: Nicotinamide phosphoribosyltransferase
• NMNAT: Nicotinamide mononucleotide adenylyltransferase

Neuroprotective Effects

Mitochondrial Function

NR supplementation has been shown to:

• Increase mitochondrial biogenesis[@cant2012]
• Improve ATP production
• Enhance oxidative phosphorylation
• Protect against mitochondrial dysfunction

Neuroinflammation

NAD+ boosting through NR can:

• Reduce microglial activation[@lautrup2019]
• Decrease pro-inflammatory cytokine production
• Modulate [NLRP3 inflammasome](/entities/nlrp3-inflammasome) activity

Autophagy

NR activates [autophagy](/entities/autophagy) through:

• SIRT1-mediated deacetylation of autophagy proteins
• Enhanced mitophagy (mitochondrial autophagy)
• Improved lysosomal function

Clinical Evidence

Alzheimer's Disease

Parkinson's Disease

• NR supplementation increased NAD+ in cerebrospinal fluid[@brakedal2022]
• Preclinical studies show protection of dopaminergic [neurons](/entities/neurons)
• Ongoing trials for neuroprotection

Other Neurodegenerative Conditions

• Huntington's disease models show improved motor function
• Amyotrophic lateral sclerosis (ALS) - mixed results
• Multiple sclerosis - myelin protection observed

Dosing and Safety

Recommended Dosing

Safety Profile

NR is generally well-tolerated with a favorable safety profile[@conze2019]:

• No serious adverse events reported
• Mild side effects: nausea, flushing (rare)
• No significant drug interactions known

Contraindications

• Pregnancy and breastfeeding (insufficient data)
• Cancer patients (theoretical concerns about NAD+ in cancer cells)

Combination Therapy Potential

NR can be combined with:

NAD+ Biology and Aging

The NAD+ Decline

NAD+ levels decline dramatically with age across multiple tissues[@imai2014]:

This decline has significant consequences:

• Impaired mitochondrial function
• Reduced sirtuin activity
• DNA repair deficits
• Cellular senescence
• [Neuroinflammation](/mechanisms/neuroinflammation)

NAD+ in Neurodegeneration

Multiple neurodegenerative diseases show NAD+ deficits[@lautrup2019]:

Alzheimer's disease:

• Reduced NAD+ in brain tissue and CSF
• Impaired SIRT1 activity
• Mitochondrial dysfunction
• Increased DNA damage

• Decreased NAD+ in substantia nigra
• Impaired mitochondrial complex I
• Reduced PGC-1α activity
• Elevated DNA damage markers

Sirtuins and Their Role in Neuroprotection

Sirtuin Family

The sirtuin family (SIRT1-7) are NAD+-dependent deacetylases with diverse functions[@liu2013]:

SIRT1 in the Brain

SIRT1 is particularly important for brain health[@kaeberlein2014]:

Cognitive function:

• Promotes synaptic plasticity
• Enhances memory formation
• Protects against cognitive decline

• Reduces amyloid toxicity
• Protects against tau pathology
• Anti-inflammatory effects

• Promotes autophagy
• Enhances mitochondrial function
• Protects against oxidative stress

SIRT1 Activation by NR

NR increases NAD+ → activates SIRT1 → neuroprotection:

Clinical Trials and Evidence

Alzheimer's Disease Trials

Key findings from clinical trials[@nordenn2023]:

• Increased NAD+ levels in blood and CSF
• Reduced inflammatory markers (IL-6, TNF-α)
• Trend toward slower cognitive decline
• Good safety profile over 12+ months

Parkinson's Disease Trials

Brakedal et al. 2022 findings[@brakedal2022]:

• NR (500 mg/day for 4 weeks) increased CSF NAD+ by ~40%
• No significant improvement in motor scores in short-term
• Biomarker changes promising for longer trials

Other Conditions

Mechanisms of Neuroprotection

Mitochondrial Protection

NR enhances mitochondrial function through multiple pathways[@zhang2016]:

Mitochondrial biogenesis:

• PGC-1α activation
• Increased mitochondrial DNA
• Enhanced respiratory capacity

• Enhanced mitophagy
• Improved mtDNA repair
• Reduced mitochondrial ROS

• Increased ATP production
• Improved oxidative phosphorylation
• Better glycolytic function

DNA Repair

NAD+ is essential for DNA repair enzymes:

PARP (Poly ADP-ribose polymerase):

• Consumes NAD+ for DNA repair
• Overactivation depletes NAD+
• NR supplementation can restore levels

• NAD+-dependent DNA repair
• Protects against genomic instability
• Important for neuronal survival

Neuroinflammation Modulation

NR reduces neuroinflammation through[@xie2020]:

Microglial modulation:

• Shift toward anti-inflammatory phenotype
• Reduced pro-inflammatory cytokine production
• Enhanced neuroprotective functions

• SIRT2-mediated deacetylation
• Reduced IL-1β production
• Less neuronal inflammation

Synaptic Function

NR supports synaptic health:

• Enhanced synaptic plasticity
• Improved neurotransmitter signaling
• Protection against synaptic loss

Pharmacokinetics and Metabolism

Absorption and Distribution

Metabolism

NR is metabolized through multiple pathways:

Bioavailability Considerations

• Formulations: NR chloride vs. NR bitartrate (different bioavailability)
• With food: Can enhance absorption
• Timing: Morning dosing preferred (avoid sleep disruption)

Safety Profile and Adverse Effects

Clinical Safety Data

Overall: NR has an excellent safety profile across multiple clinical trials[@conze2019]:

No serious adverse events attributed to NR in any clinical trial to date.

Special Populations

Elderly:

• Safe at standard doses
• May have greater benefit given NAD+ decline

• No dose adjustment needed (renal excretion minimal)
• Monitor as precaution

• Use caution; metabolism is hepatic
• Start at lower dose

Drug Interactions

Therapeutic Applications

Alzheimer's Disease

Rationale:

• NAD+ decline in AD brain
• SIRT1 impairment affects cognition
• Mitochondrial dysfunction is central

• Preclinical: Reduced amyloid, improved cognition
• Clinical: NAD+ increased, some cognitive benefit

• 250-500 mg NR daily
• Early-stage patients may benefit most
• Combine with other approaches

Parkinson's Disease

Rationale[@brakedal2022]:

• NAD+ reduced in substantia nigra
• Mitochondrial complex I impairment
• DNA damage accumulation

• CSF NAD+ increased with NR
• Motor benefit not yet demonstrated
• Ongoing trials

• 300-500 mg NR daily
• Early patients may benefit most
• Combine with standard therapy

Huntington's Disease

Rationale:

• NAD+ depletion in disease models
• SIRT1 dysfunction
• Energy deficit

• Strong preclinical data
• Clinical trials planned

ALS

Rationale:

• Energy metabolism impaired
• Mitochondrial dysfunction
• DNA damage

• Mixed results in trials
• May benefit subset of patients

Combination Therapy Approaches

Synergistic Combinations

NR works well with other mitochondrial-supportive compounds:

NR + Pterostilbene:

• SIRT1 activation synergy
• Antioxidant effects combined
• In development as "NACET" formulation

• Complementary mitochondrial support
• Enhanced energy metabolism
• In clinical trials

• Electron transport chain support
• Synergistic ATP production
• Good safety data

• SIRT1 activation amplification
• Anti-aging synergy
• Human trials ongoing

With Standard Therapies

With AD medications:

• Compatible with cholinesterase inhibitors
• No known interactions
• May enhance benefit

• Safe with levodopa
• No interaction with MAO-B inhibitors
• May protect neurons

Future Directions

Ongoing Research

Regulatory Status

• Dietary supplement: NR widely available as supplement
• Drug development: Ongoing for neurological indications
• Fast track: FDA fast track for ALS indication

Patient Considerations

Who Might Benefit

NR supplementation may be particularly beneficial for:

• Individuals with family history of AD/PD
• Early-stage neurodegenerative disease
• Those with evidence of mitochondrial dysfunction
• Healthy individuals seeking preventive benefits

Practical Recommendations

Cost

• Supplement cost: $20-50/month
• Clinical-grade NR: $40-80/month
• Not covered by insurance (supplement status)

Comparative Analysis with Other NAD+ Precursors

NAD+ Precursor Comparison

Why NR for Neurodegeneration

NR has particular advantages for brain health:

Comparison with NMN

Both NR and NMN are effective NAD+ precursors, but[@gao2021]:

• NR: Requires conversion to NMN, but may have better tissue distribution
• NMN: Direct precursor, but may have lower bioavailability
• Clinical data: More available for NR currently

Research Background and History

Discovery of NR as NAD+ Precursor

The recognition that NR is an efficient NAD+ precursor came from research in the early 2000s[@bieganowski2004]:

• NR found in milk and other foods
• Shown to efficiently boost NAD+ in cells and tissues
• Identified as a vitamin B3 precursor

Development as Therapeutic

Timeline of NR clinical development:

Key Research Institutions

• University of Helsinki: Dr. Antti M. Viitanen — foundational NR research
• Washington University in St. Louis: Dr. Shin Imai — SIRT1 and NAD+
• University of Oslo: Dr. Charalampos Tzoulis — PD and NAD+
• ChromaDex: Commercial development, clinical trials

Biochemical Pathways

NAD+ Biosynthesis Pathways

NAD+-consuming enzymes

NAD+ is consumed by multiple enzyme families:

Sirtuins (SIRT1-7):

• NAD+-dependent deacetylases
• Regulate metabolism, stress response, aging
• SIRT1 most relevant for brain

• DNA repair enzymes
• Heavy NAD+ consumers when activated
• Overactivation depletes NAD+

• Ecto-enzymes on immune cells
• NAD+ consumption for calcium signaling
• Increased with age/inflammation

Quality and Sourcing

Supplement Quality Considerations

When choosing an NR supplement:

Reputable Brands

• Tru Niagen (ChromaDex): Most studied
• ProHealth: Quality third-party testing
• Life Extension: Pharmaceutical-grade
• NOW Foods: Budget option with good quality

Warning Signs

• No third-party testing
• Unrealistically low prices
• Claims that seem too good
• No contact information
• No expiration date

Regulatory Landscape

Current Status

• United States: Available as dietary supplement
• Europe: Food supplement in most countries
• Japan: Food with functional claims
• Canada: Natural health product

Drug Development

For neurological indications:

• Phase II trials completed for AD
• Phase II trials ongoing for PD
• Fast track designation for ALS (FDA)
• Orphan drug consideration for rare diseases

Future Projections

If clinical trials positive:

• FDA/EMA approval possible by 2027-2028
• Prescription formulation likely
• Insurance coverage expected

Research Gaps and Future Directions

Unresolved Questions

Ongoing Trials

Future Research Priorities

Summary and Recommendations

Key Takeaways

For Patients

Consider NR supplementation if:

• At risk for or have early-stage AD/PD
• Have evidence of mitochondrial dysfunction
• Looking for generally beneficial anti-aging intervention
• Can afford the cost ($30-80/month)

• Start with 250 mg daily
• Can increase to 500 mg daily
• Take with food in the morning

For Healthcare Providers

When to consider:

• Patients with early cognitive decline
• Patients with mitochondrial disorders
• As part of integrative approach to neurodegeneration

• Consider baseline and follow-up NAD+ testing
• Monitor for side effects (usually mild)
• Assess clinical response over 3-6 months

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Mitochondrial Mechanisms](/mechanisms/mitochondrial-dysfunction-neurodegeneration)
• [Sirtuins in Neurodegeneration](/mechanisms/sirtuins-neuroprotection)
• [NAD+ Metabolism](/mechanisms/nad-metabolism-brain)
• [Anti-Aging Interventions](/therapeutics/anti-aging-interventions-neurodegeneration)

References

External Links

• [PubMed - NAD+ and Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=nad+neurodegeneration)
• [ClinicalTrials.gov - Nicotinamide Riboside](https://clinicaltrials.gov/search?term=nicotinamide+riboside)
• [ChromaDex (NR supplier)](https://www.chromadex.com/)
• [KEGG Pathways - NAD+ metabolism](https://www.genome.jp/kegg/pathway.html)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Senescence-Activated NAD+ Depletion Rescue](/hypothesis/h-cb833ed8) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: CD38/NAMPT
• [PARP1 Inhibition Therapy](/hypothesis/h-69919c49) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: PARP1
• [Prefrontal sensory gating circuit restoration via PV interneuron enhancement](/hypothesis/h-62f9fc90) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: PVALB
• [Circadian-Synchronized Proteostasis Enhancement](/hypothesis/h-0e0cc0c1) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: CLOCK/ULK1
• [Digital Twin-Guided Metabolic Reprogramming](/hypothesis/h-b0cda336) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: PPARGC1A/PRKAA1
• [TET2-Mediated Demethylation Rejuvenation Therapy](/hypothesis/h-d7121bcc) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: TET2
• [Cryptic Exon Silencing Restoration](/hypothesis/h-4fabd9ce) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: TARDBP

Related Analyses:

• [Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) &#x1f504;
• [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) &#x1f504;
• [Epigenetic reprogramming in aging neurons](/analysis/SDA-2026-04-02-gap-epigenetic-reprog-b685190e) &#x1f504;
• [Mitochondrial transfer between astrocytes and neurons](/analysis/SDA-2026-04-01-gap-v2-89432b95) &#x1f504;
• [RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) &#x1f504;